BIIB033 (opicinumab)

DRUG2 trials

Sponsors

Biogen

Conditions

Acute Optic NeuritisMultiple Sclerosis

Phase 1

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

CompletedNCT02833142

BiogenAcute Optic Neuritis, Multiple Sclerosis

Start: 2016-07-31End: 2016-11-30Updated: 2016-12-08

Phase 2

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

TerminatedNCT03222973

BiogenMultiple Sclerosis

Start: 2017-11-15End: 2021-02-12Updated: 2022-04-28

Related Papers

Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.

2025-12-26

Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis

Multiple Sclerosis Journal2023-04-1057 citations

Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site

mAbs2020-01-0120 citations

200 AFFINITY: opicinumab in a targeted population of MS patients

Journal of Neurology Neurosurgery & Psychiatry2019-11-141 citations

Phase 2 AFFINITY Trial Evaluates Opicinumab in a Targeted Population of Patients With Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics (P3.2-072)

Neurology2019-04-094 citations